Characterization of CYP2C19*17 Polymorphism in a Portuguese Population Sample Relevant for Proton Pump Inhibitor Therapy—A Pilot Study

The interindividual variability of Proton Pump Inhibitor (PPI) therapy results from the phenotype associated with cytochrome P450 2C19 (CYP2C19) gene, namely CYP2C19*17 allele. Our aim was to characterize patients’ genetic undergoing PPI therapy. A sample 33 oral mucosa cells Portuguese pharmacy patients collected, followed by genotyping. allelic frequencies CYP2C19*1 (-806C) and (-806T) were 71.2% 28.8%, respectively. genotypic for CYP2C19*1/*1 CYP2C19*1/*17 42.4% 57.6%, respectively, 19 these may have a Rapid Metabolizer (RM) pharmaceutical opinion letter, based on evidence.